Enhancing effects of acute exposure to cannabis smoke on working memory performance.
Cannabinoid
Cannabis
Executive function
Marijuana
Smoke
Working memory
Journal
Neurobiology of learning and memory
ISSN: 1095-9564
Titre abrégé: Neurobiol Learn Mem
Pays: United States
ID NLM: 9508166
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
22
08
2018
revised:
27
11
2018
accepted:
01
12
2018
pubmed:
7
12
2018
medline:
26
11
2019
entrez:
7
12
2018
Statut:
ppublish
Résumé
Numerous preclinical studies show that acute cannabinoid administration impairs cognitive performance. Almost all of this research has employed cannabinoid injections, however, whereas smoking is the preferred route of cannabis administration in humans. The goal of these experiments was to systematically determine how acute exposure to cannabis smoke affects working memory performance in a rat model. Adult male (n = 15) and female (n = 16) Long-Evans rats were trained in a food-motivated delayed response working memory task. Prior to test sessions, rats were exposed to smoke generated by burning different numbers of cannabis or placebo cigarettes, using a within-subjects design. Exposure to cannabis smoke had no effect on male rats' performance, but surprisingly, enhanced working memory accuracy in females, which tended to perform less accurately than males under baseline conditions. In addition, cannabis smoke enhanced working memory accuracy in a subgroup of male rats that performed comparably to the worst-performing females. Exposure to placebo smoke had no effect on performance, suggesting that the cannabinoid content of cannabis smoke was critical for its effects on working memory. Follow-up experiments showed that acute administration of either Δ9-tetrahydrocannabinol (0.0, 0.3, 1.0, 3.0 mg/kg) or the cannabinoid receptor type 1 antagonist rimonabant (0.0, 0.2, 0.6, 2.0 mg/kg) impaired working memory performance. These results indicate that differences in the route, timing, or dose of cannabinoid administration can yield distinct cognitive outcomes, and highlight the need for further investigation of this topic.
Identifiants
pubmed: 30521850
pii: S1074-7427(18)30277-6
doi: 10.1016/j.nlm.2018.12.001
pmc: PMC6563837
mid: NIHMS1518285
pii:
doi:
Substances chimiques
Cannabinoids
0
Cannabidiol
19GBJ60SN5
Dronabinol
7J8897W37S
Cannabinol
7UYP6MC9GH
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
151-162Subventions
Organisme : NIDA NIH HHS
ID : R21 DA039349
Pays : United States
Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.
Références
J Neurosci. 1999 May 15;19(10):4065-72
pubmed: 10234034
Life Sci. 1999;65(6-7):715-23
pubmed: 10462072
Behav Brain Res. 1999 Feb 15;99(1):27-34
pubmed: 10512569
Psychopharmacology (Berl). 2000 Jan;147(4):436-8
pubmed: 10672638
Eur J Pharmacol. 2000 Jul 7;399(2-3):141-9
pubmed: 10884513
Neuroreport. 2000 Aug 3;11(11):2581-5
pubmed: 10943726
J Neurosci. 2000 Dec 1;20(23):8932-42
pubmed: 11102504
Psychopharmacology (Berl). 2001 Sep;157(2):142-50
pubmed: 11594438
JAMA. 2002 Mar 6;287(9):1123-31
pubmed: 11879109
J Neurosci. 2002 May 1;22(9):3326-31
pubmed: 11978807
Neurology. 2002 Nov 12;59(9):1337-43
pubmed: 12427880
Clin Pharmacokinet. 2003;42(4):327-60
pubmed: 12648025
Mol Psychiatry. 2004 May;9(5):531-8
pubmed: 14569273
Psychopharmacology (Berl). 2004 Dec;177(1-2):141-50
pubmed: 15290005
Behav Brain Res. 2004 Sep 23;154(1):77-83
pubmed: 15302113
Psychopharmacology (Berl). 2004 Nov;176(2):214-22
pubmed: 15502936
Neuropharmacology. 2004 Dec;47(8):1170-9
pubmed: 15567426
Eur J Pharmacol. 2004 Dec 3;506(1):63-9
pubmed: 15588625
Neurosci Biobehav Rev. 2005 Jan;28(8):811-25
pubmed: 15642623
Pharmacol Biochem Behav. 2005 Jun;81(2):319-30
pubmed: 15925403
Life Sci. 2005 Sep 30;77(20):2471-8
pubmed: 15958268
Psychopharmacology (Berl). 2006 Apr;185(3):358-68
pubmed: 16521034
Behav Brain Res. 2006 Jul 15;171(1):116-26
pubmed: 16677723
Psychopharmacology (Berl). 2006 Aug;187(2):245-59
pubmed: 16752140
J Psychiatry Neurosci. 2007 Jan;32(1):30-52
pubmed: 17245472
J Pharmacol Exp Ther. 2007 Sep;322(3):1067-75
pubmed: 17586723
Physiol Behav. 2007 Dec 5;92(5):939-50
pubmed: 17716698
Behav Pharmacol. 2007 Sep;18(5-6):571-80
pubmed: 17762525
Neuroimage. 2008 Feb 15;39(4):1533-41
pubmed: 18077184
Endocrinology. 2008 Jun;149(6):3176-83
pubmed: 18292188
Behav Brain Res. 2009 Jun 8;200(1):134-43
pubmed: 19373979
Neuropsychopharmacology. 2009 Sep;34(10):2208-17
pubmed: 19440192
Behav Brain Res. 2009 Nov 5;203(2):264-9
pubmed: 19460405
Trends Pharmacol Sci. 2009 Oct;30(10):515-27
pubmed: 19729208
Psychopharmacology (Berl). 2010 Jan;208(1):143-58
pubmed: 19936715
Pharmacol Rep. 2009 Nov-Dec;61(6):1000-7
pubmed: 20081234
Pharmacol Biochem Behav. 2010 Jun;95(4):401-9
pubmed: 20211642
Neuropsychopharmacology. 2010 Aug;35(9):1879-85
pubmed: 20428110
Br J Pharmacol. 2010 Sep;161(1):103-12
pubmed: 20718743
Psychopharmacology (Berl). 2011 Mar;214(2):495-504
pubmed: 21086118
Br J Pharmacol. 2011 Aug;163(7):1391-401
pubmed: 21323910
Dev Psychobiol. 2011 Nov;53(7):724-31
pubmed: 21432847
Psychopharmacology (Berl). 2011 Nov;218(2):443-57
pubmed: 21667074
Brain Res. 2011 Sep 21;1413:32-42
pubmed: 21840504
Pharmacol Biochem Behav. 2011 Nov;100(1):109-18
pubmed: 21871478
Behav Brain Res. 2012 Oct 1;234(2):375-9
pubmed: 22814113
Exp Brain Res. 2012 Sep;221(4):437-48
pubmed: 22821081
Neuropsychol Rev. 2013 Jun;23(2):117-37
pubmed: 23129391
Neurosci Biobehav Rev. 2013 Nov;37(9 Pt A):1976-84
pubmed: 23164814
Neuroscience. 2013 Apr 3;235:51-8
pubmed: 23333671
Iran J Psychiatry. 2012 Fall;7(4):149-56
pubmed: 23408483
Neurobiol Aging. 2013 Sep;34(9):2164-74
pubmed: 23601673
Curr Pharm Des. 2014;20(13):2100-13
pubmed: 23829370
J Adolesc Health. 2014 Feb;54(2):235-40
pubmed: 24119417
Pharmacol Biochem Behav. 2014 Mar;118:30-5
pubmed: 24412835
Neurosci Biobehav Rev. 2014 May;42:116-31
pubmed: 24582908
J Neurosci. 2014 Mar 5;34(10):3457-66
pubmed: 24599447
Neurobiol Learn Mem. 2015 Jan;117:60-70
pubmed: 24642448
J Pharmacol Toxicol Methods. 2014 Jul-Aug;70(1):120-7
pubmed: 24973534
Trends Mol Med. 2015 Jul;21(7):450-60
pubmed: 26070271
Behav Neurosci. 2016 Feb;130(1):50-61
pubmed: 26653713
Biol Psychiatry. 2016 Apr 1;79(7):557-67
pubmed: 26858214
PLoS One. 2016 Apr 11;11(4):e0153327
pubmed: 27065006
Neuropharmacology. 2016 Oct;109:112-120
pubmed: 27256501
Neurobiol Aging. 2016 Sep;45:88-97
pubmed: 27459929
Neuropsychopharmacology. 2017 Apr;42(5):989-1000
pubmed: 27582345
Life Sci. 1989;45(6):465-75
pubmed: 2770412
J Neurosci. 2016 Dec 14;36(50):12537-12548
pubmed: 27807032
J Neurosci Res. 2017 Jan 2;95(1-2):260-269
pubmed: 27870448
Am J Dis Child. 1989 Oct;143(10):1214-9
pubmed: 2801665
Subst Abuse. 2017 Apr 07;11:1178221817701739
pubmed: 28469427
Nat Med. 2017 Jun;23(6):782-787
pubmed: 28481360
Psychol Med. 2017 Nov;47(15):2708-2719
pubmed: 28558859
Front Behav Neurosci. 2017 Jul 21;11:137
pubmed: 28785210
Neurobiol Aging. 2018 Jan;61:177-186
pubmed: 29107185
Neuropsychopharmacology. 2018 Jan;43(1):213
pubmed: 29192672
Brain Sci. 2018 Feb 27;8(3):null
pubmed: 29495540
Neuropharmacology. 2018 Jul 15;137:133-140
pubmed: 29758385
Biol Psychiatry. 2018 Oct 15;84(8):601-610
pubmed: 29861097
J Pharm Biomed Anal. 2018 Oct 25;160:119-125
pubmed: 30077950
Pharmacol Rev. 1986 Mar;38(1):21-43
pubmed: 3012605
Pharmacol Biochem Behav. 1973 Jul-Aug;1(4):371-8
pubmed: 4777575
Life Sci I. 1971 Jan 1;10(1):49-59
pubmed: 5541586
Biol Psychiatry. 1995 May 15;37(10):731-9
pubmed: 7640328
Neuron. 1995 Mar;14(3):477-85
pubmed: 7695894
JAMA. 1996 Feb 21;275(7):521-7
pubmed: 8606472
Neuropsychopharmacology. 1997 Jun;16(6):426-32
pubmed: 9165498
Neurobiol Dis. 1998 Dec;5(6 Pt B):474-82
pubmed: 9974179